메뉴 건너뛰기




Volumn 117, Issue 2, 2010, Pages 81-87

Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction

Author keywords

Acute myocardial infarction; Antiplatelet agents; Cytochrome P450; Mortality; Polymorphism; Reperfusion

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; WARFARIN;

EID: 77957310177     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320093     Document Type: Article
Times cited : (23)

References (25)
  • 1
    • 75949128633 scopus 로고    scopus 로고
    • Antiplatelet therapies for the treatment of cardiovascular disease
    • Michelson AD: Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010;9:154-169.
    • (2010) Nat. Rev. Drug Discov. , vol.9 , pp. 154-169
    • Michelson, A.D.1
  • 7
    • 58749090547 scopus 로고    scopus 로고
    • French registry of acute ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) investigators: Genetic determinants of response to clopidogrel and cardiovascular events
    • Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators: Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.
    • (2009) N. Engl. J. Med. , vol.360 , pp. 363-375
    • Simon, T.1    Verstuyft, C.2    Mary-Krause, M.3    Quteineh, L.4    Drouet, E.5    Méneveau, N.6    Steg, P.G.7    Ferrières, J.8    Danchin, N.9    Becquemont, L.10
  • 10
    • 0033609457 scopus 로고    scopus 로고
    • Can coronary blood flow velocity pattern after primary percutaneous transluminal coronary angiography predict recovery of regional left ventricular function in patients with acute myocardial infarction?
    • Kawamoto T, Yoshida K, Akasaka T, Hozumi T, Takagi T, Kaji S, Ueda Y: Can coronary blood flow velocity pattern after primary percutaneous transluminal coronary angiography predict recovery of regional left ventricular function in patients with acute myocardial infarction? Circulation 1999;100:339-345.
    • (1999) Circulation , vol.100 , pp. 339-345
    • Kawamoto, T.1    Yoshida, K.2    Akasaka, T.3    Hozumi, T.4    Takagi, T.5    Kaji, S.6    Ueda, Y.7
  • 11
    • 0033809487 scopus 로고    scopus 로고
    • Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction
    • Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, Matsui H, Toki Y, Ito T, Hayakawa T: Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36:1202-1209.
    • (2000) J. Am. Coll. Cardiol. , vol.36 , pp. 1202-1209
    • Morishima, I.1    Sone, T.2    Okumura, K.3    Tsuboi, H.4    Kondo, J.5    Mukawa, H.6    Matsui, H.7    Toki, Y.8    Ito, T.9    Hayakawa, T.10
  • 12
    • 0242552079 scopus 로고    scopus 로고
    • Primary angioplasty in myocardial infarction (PAMI) investigators: Clinical and angiographic correlates and outcomes of suboptimal coronary flow in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention
    • Mehta RH, Harjai KJ, Cox D, Stone GW, Brodie B, Boura J, O'Neill W, Grines CL; Primary Angioplasty in Myocardial Infarction (PAMI) Investigators: Clinical and angiographic correlates and outcomes of suboptimal coronary flow in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1739-1746.
    • (2003) J. Am. Coll. Cardiol. , vol.42 , pp. 1739-1746
    • Mehta, R.H.1    Harjai, K.J.2    Cox, D.3    Stone, G.W.4    Brodie, B.5    Boura, J.6    O'Neill, W.7    Grines, C.L.8
  • 13
    • 1442311386 scopus 로고    scopus 로고
    • Impaired myocardial perfusion is a major explanation of the poor outcome observed in patients undergoing primary angioplasty for ST-segment-elevation myocardial infarction and signs of heart failure
    • De Luca G, van't Hof AW, de Boer MJ, Hoorntje JC, Gosselink AT, Dambrink JH, Ottervanger JP, Zijlstra F, Suryapranata H: Impaired myocardial perfusion is a major explanation of the poor outcome observed in patients undergoing primary angioplasty for ST-segment-elevation myocardial infarction and signs of heart failure. Circulation 2004;109:958-961.
    • (2004) Circulation , vol.109 , pp. 958-961
    • De Luca, G.1    Van't Hof, A.W.2    De Boer, M.J.3    Hoorntje, J.C.4    Gosselink, A.T.5    Dambrink, J.H.6    Ottervanger, J.P.7    Zijlstra, F.8    Suryapranata, H.9
  • 14
    • 1542409911 scopus 로고    scopus 로고
    • Impact of microvascular dysfunction on left ventricular remodelling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction
    • Bolognese L, Carrabba N, Parodi G, Santoro GM, Buonamici P, Cerisano G, Antoniucci D: Impact of microvascular dysfunction on left ventricular remodelling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004;109:1121-1126.
    • (2004) Circulation , vol.109 , pp. 1121-1126
    • Bolognese, L.1    Carrabba, N.2    Parodi, G.3    Santoro, G.M.4    Buonamici, P.5    Cerisano, G.6    Antoniucci, D.7
  • 15
    • 0033822124 scopus 로고    scopus 로고
    • Myocardial infarction redefined - A consensus document of the joint European society of cardiology/American college of cardiology committee for the redefinition of myocardial infarction
    • Joint European Society of Cardiology/Amercian College of Cardiology Committee
    • The Joint European Society of Cardiology/Amercian College of Cardiology Committee: Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-1513.
    • (2000) Eur. Heart J. , vol.21 , pp. 1502-1513
  • 16
    • 0023258694 scopus 로고
    • Thrombolysis in myocardial infarction (TIMI) trial, phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge
    • Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, et al: Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 1987;76:142-154.
    • (1987) Circulation , vol.76 , pp. 142-154
    • Chesebro, J.H.1    Knatterud, G.2    Roberts, R.3    Borer, J.4    Cohen, L.S.5    Dalen, J.6    Dodge, H.T.7    Francis, C.K.8    Hillis, D.9    Ludbrook, P.10
  • 17
    • 33747874088 scopus 로고    scopus 로고
    • A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial
    • ALBION Trial Investigators
    • Montalescot G, Sideris G, Meuleman C, Baldit-Sollier C, Lellouche N, Steg PG, Slama M, Milleron O, Collet JP, Henry P, Beygui F, Drouet L; ALBION Trial Investigators: A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006;48:931-938.
    • (2006) J. Am. Coll. Cardiol. , vol.48 , pp. 931-938
    • Montalescot, G.1    Sideris, G.2    Meuleman, C.3    Baldit-Sollier, C.4    Lellouche, N.5    Steg, P.G.6    Slama, M.7    Milleron, O.8    Collet, J.P.9    Henry, P.10    Beygui, F.11    Drouet, L.12
  • 18
    • 67849083515 scopus 로고    scopus 로고
    • Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction
    • Fefer P, Hod H, Hammerman H, Segev A, Beinart R, Boyko V, Behar S, Matetzky S: Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Am J Cardiol 2009;104:514-518.
    • (2009) Am. J. Cardiol. , vol.104 , pp. 514-518
    • Fefer, P.1    Hod, H.2    Hammerman, H.3    Segev, A.4    Beinart, R.5    Boyko, V.6    Behar, S.7    Matetzky, S.8
  • 20
    • 78650413883 scopus 로고    scopus 로고
    • CYP2C19 and clinical outcomes with clopidogrel: A collaborative meta-analysis
    • Orlando
    • Mega JL: CYP2C19 and clinical outcomes with clopidogrel: a collaborative meta-analysis. American Heart Association Conference, Orlando, 2009.
    • (2009) American Heart Association Conference
    • Mega, J.L.1
  • 21
    • 67649654260 scopus 로고    scopus 로고
    • Antiplatelet drug 'resistance'. Part 1: Mechanisms and clinical measurements
    • Sweeny JM, Gorog DA, Fuster V: Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009;6:273-82.5.
    • (2009) Nat. Rev. Cardiol. , vol.6 , pp. 273-825
    • Sweeny, J.M.1    Gorog, D.A.2    Fuster, V.3
  • 25
    • 73549106603 scopus 로고    scopus 로고
    • Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: The 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel)
    • 3T/2R Investigators
    • Campo G, Valgimigli M, Frangione A, Luccarelli S, Cangiano E, Cavazza C, Fileti L, Ferrari R; 3T/2R Investigators: Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel). J Am Coll Cardiol 2010;55:255-256.
    • (2010) J. Am. Coll. Cardiol. , vol.55 , pp. 255-256
    • Campo, G.1    Valgimigli, M.2    Frangione, A.3    Luccarelli, S.4    Cangiano, E.5    Cavazza, C.6    Fileti, L.7    Ferrari, R.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.